Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Inflammatory Bowel Disease: How It Works Alongside Biologics and Steroids
Transcript
- 0:00SPEAKER_00: Welcome to the Cerona Cell Podcast.
- 0:02SPEAKER_00: So imagine for the second that your own immune system just decides to mistake your lunch for, I don't know, a deadly virus.
- 0:09SPEAKER_01: Right.
- 0:09SPEAKER_01: Yeah.
- 0:09SPEAKER_01: It just completely overreacts.
- 0:11SPEAKER_00: Exactly.
- 0:11SPEAKER_00: And it turns your digestive tract into this microscopic continuous battlefield for millions of people dealing with inflammatory bowel disease or IBD.
- 0:22SPEAKER_00: That is not some dramatic metaphor.
- 0:24SPEAKER_00: It's just their exhausting daily reality.
- 0:26SPEAKER_01: It really is.
- 0:27SPEAKER_01: And, you know, navigating that reality can feel completely overwhelming for you, the patient, especially with all the noise out there.
- 0:34SPEAKER_00: Yeah, which is why today we are doing a deep dive into a really fascinating May 5, 2026 publication.
- 0:40SPEAKER_00: We are exploring a completely new paradigm in treating these complex conditions, specifically focusing on where stem cell therapy actually fits in.
- 0:49SPEAKER_01: Right, because it's not about replacing everything else.
- 0:50SPEAKER_01: It fits alongside traditional treatments.
- 0:53SPEAKER_00: Exactly, like biologics and steroids.
- 0:55SPEAKER_00: And to sort of anchor this science in the real world, we're also going to look at how a specific regenerative medicine center over in Qualobor, uh Sorona cell, is approaching this.
- 1:04SPEAKER_01: Yeah, and I think framing this conversation correctly from the very first minute is just it's vital.
- 1:10SPEAKER_01: Anyone who's dealing with chronic conditions, you know, like Crohn's disease or ulcerative colitis, they know the landscape is unfortunately filled with, well, quick fix medical hype.
- 1:20SPEAKER_00: Oh, absolutely.
- 1:20SPEAKER_00: Magic pills and all that.
- 1:21SPEAKER_01: Exactly.
- 1:22SPEAKER_01: And we are bypassing that entirely today.
- 1:25SPEAKER_01: The focus here is on structured, science-led care.
- 1:29SPEAKER_01: We aren't looking at a magic cure today.
- 1:31SPEAKER_01: Right.
- 1:31SPEAKER_01: What we are really unpacking is this evolving, highly fascinating puzzle of immune modulation.
- 1:38SPEAKER_01: It's about long-term stability for patients dealing with really complex chronic conditions.
- 1:44SPEAKER_00: Okay, so before we get into how the newest therapies work, we kind of need to understand exactly what they're trying to fix.
- 1:49SPEAKER_01: Yeah, we have to look at the battlefield itself.
- 1:51SPEAKER_00: Aaron Powell So let's talk about the reality of IBD.
- 1:53SPEAKER_00: When we talk about Crohn's and ulcerative colitis, we are talking about a scenario where the body's primary defense mechanism makes this catastrophic error.
- 2:03SPEAKER_01: Aaron Powell Right.
- 2:04SPEAKER_01: It's a massive case of mistaken identity.
- 2:07SPEAKER_01: Instead of targeting harmful bacteria or some rogue virus, the immune system turns its weapons directly on the gut lining itself.
- 2:15SPEAKER_00: Aaron Powell Which causes continuous inflammation.
- 2:18SPEAKER_01: Trevor Burrus Exactly.
- 2:19SPEAKER_01: Continuous cyclical inflammation that just repeatedly damages the intestinal walls over time.
- 2:24SPEAKER_00: Aaron Powell And the sources use this brilliant real-world example to illustrate the physical toll of that, the lettuce example.
- 2:31SPEAKER_01: Aaron Powell Oh, yeah.
- 2:32SPEAKER_01: The lettuce analogy is perfect because you might think, why can't someone with severe Crohn's just eat a really healthy raw salad?
- 2:39SPEAKER_00: Trevor Burrus Right.
- 2:39SPEAKER_00: It's just vegetables, right?
- 2:40SPEAKER_01: Trevor Burrus, well, raw fibrous foods are inherently difficult to digest.
- 2:44SPEAKER_01: So when your intestinal lining is severely inflamed, you know, swollen, and literally covered in these macroscopic wounds, forcing raw fiber through that system is mechanically terrible.
- 2:54SPEAKER_00: Aaron Powell It's like rubbing coarse sandpaper over a third-degree sunburn.
- 2:58SPEAKER_01: Aaron Powell That is exactly what it feels like.
- 2:59SPEAKER_01: The result is just immense pain, severe bloating, and even more physical irritation to a mucosa lining that is already compromised.
- 3:06SPEAKER_01: Trevor Burrus, Jr.
- 3:07SPEAKER_00: Which forces patients to alter their entire existence just to avoid the sandpaper, basically.
- 3:10SPEAKER_01: Aaron Powell Right.
- 3:11SPEAKER_01: They completely change their diet.
- 3:12SPEAKER_00: Aaron Powell But I mean, avoiding the lettuce is purely a symptom management strategy, isn't it?
- 3:17SPEAKER_00: It doesn't actually fix anything.
- 3:18SPEAKER_01: Aaron Powell No, it doesn't.
- 3:19SPEAKER_01: It absolutely improves the day-to-day quality of life, but it doesn't communicate with the immune system to tell it to stop attacking.
- 3:28SPEAKER_01: And it certainly does not rebuild the core tissue that has already been eroded away.
- 3:33SPEAKER_00: Aaron Powell Okay, so that brings us to the current standard of care.
- 3:37SPEAKER_00: Right now, the heavy hitters in modern gastroenterology are basically steroids and biologics.
- 3:43SPEAKER_01: Yeah, those are the two main pillars.
- 3:45SPEAKER_00: So let's unpack this with an analogy.
- 3:47SPEAKER_01: Yeah.
- 3:47SPEAKER_00: If your gut is a house on fire, steroids are essentially the fire extinguisher, right?
- 3:52SPEAKER_00: They come in fast, put out the immediate flames that acute inflammation.
- 3:55SPEAKER_01: Right.
- 3:55SPEAKER_01: They smother the fire very quickly, but they suppress the whole immune system to do it.
- 3:59SPEAKER_00: Yeah, which isn't great long term.
- 4:01SPEAKER_00: Yeah.
- 4:01SPEAKER_00: So you bring in biologics, which are like the state-of-the-art long-term fire prevention system, they stop the fire from sparking again.
- 4:08SPEAKER_01: That is a really great way to look at it.
- 4:10SPEAKER_00: But here is my question.
- 4:11SPEAKER_00: Even with the fire out and the prevention system installed, what actually rebuilds the burnt walls?
- 4:17SPEAKER_00: Because despite these two drugs, a lot of patients still experience ongoing disease activity.
- 4:23SPEAKER_01: That is the exact gap in the current medical arsenal.
- 4:26SPEAKER_01: You are totally right.
- 4:27SPEAKER_01: Steroids handle that rapid inflammation, and biologics do a fantastic job managing the long-term immune response, but neither of them directly heals the structural damage.
- 4:37SPEAKER_00: They don't rebuild the house.
- 4:38SPEAKER_01: No, they don't.
- 4:39SPEAKER_01: They don't have the biological instructions to tell the gut lining to knit back together.
- 4:43SPEAKER_01: And that gap in the healing process is exactly why a completely new approach is needed.
- 4:48SPEAKER_00: Okay.
- 4:49SPEAKER_00: Enter mesenchymal stem cells, or MSCs.
- 4:53SPEAKER_00: This is where we move from traditional drugs to the actual cellular mechanics of rebuilding those burnt walls.
- 4:59SPEAKER_01: Yeah, this is a very different kind of healing.
- 5:01SPEAKER_00: So what exactly are MSCs?
- 5:04SPEAKER_00: Because the literature frames them as the body's natural repair crew, right?
- 5:07SPEAKER_01: Yeah, that's the best way to think of them.
- 5:09SPEAKER_01: They are these special, highly communicative cells.
- 5:12SPEAKER_01: And the May 2026 publication details these four main pillars of how they actually work when you introduce them into the gut.
- 5:20SPEAKER_00: Okay, let's break those down.
- 5:21SPEAKER_00: What's the first pillar?
- 5:23SPEAKER_01: The first step is reducing inflammation deeply.
- 5:26SPEAKER_01: When MSCs encounter a highly inflamed environment, they actively lower the levels of inflammatory cytokines.
- 5:33SPEAKER_00: And cytokines are basically the chemical alarm bells, right?
- 5:36SPEAKER_01: Exactly.
- 5:36SPEAKER_01: They are keeping the local immune system in this state of high alert.
- 5:40SPEAKER_01: So the MSCs step in and just completely muffle those alarms.
- 5:44SPEAKER_00: Wow.
- 5:44SPEAKER_00: Okay.
- 5:44SPEAKER_00: So once the alarms are quiet, what happens next?
- 5:47SPEAKER_01: Aaron Powell Well then the local environment shifts from this chaotic destruction to a state of calm.
- 5:52SPEAKER_01: And that supports the second pillar, which is the actual physical repair of the damaged intestinal tissue.
- 5:58SPEAKER_00: Aaron Powell Oh, so the tissue can finally breathe and start to fix itself?
- 6:01SPEAKER_01: Right.
- 6:01SPEAKER_01: With that intense inflammatory pressure gone, the barrier of the gut lining can finally start to knit back together.
- 6:09SPEAKER_01: But you know, repairing the damage isn't enough if the immune system is just going to wake up and attack it again the next day.
- 6:14SPEAKER_00: Aaron Powell Right.
- 6:15SPEAKER_00: Which leads to the third pillar, I'm guessing.
- 6:16SPEAKER_01: Aaron Powell Exactly.
- 6:18SPEAKER_01: The third pillar is balancing the immune response.
- 6:20SPEAKER_01: MSCs interact directly with those rogue immune cells.
- 6:25SPEAKER_01: They basically act like diplomats, controlling them and telling them to stand down.
- 6:29SPEAKER_00: Aaron Powell Cellular diplomacy.
- 6:30SPEAKER_00: I like that.
- 6:31SPEAKER_01: Yeah.
- 6:31SPEAKER_01: They return the environment to a regulated state.
- 6:34SPEAKER_01: And then the final pillar is all about long-term stability.
- 6:37SPEAKER_01: The MSCs release these specific growth factors.
- 6:41SPEAKER_00: Wait, what do the growth factors do?
- 6:42SPEAKER_01: They send continuous healing signals to the native cells.
- 6:45SPEAKER_01: It provides this ongoing biological scaffolding for long-term mucosal healing.
- 6:50SPEAKER_01: It creates a sustained regenerative environment.
- 6:53SPEAKER_00: Aaron Powell Okay, so they muffle the alarms, rebuild the walls, retrain the arsonists, and then leave behind a blueprint for long-term repair.
- 7:00SPEAKER_00: That sounds amazing.
- 7:01SPEAKER_01: Aaron Powell It is incredibly sophisticated biology.
- 7:03SPEAKER_00: Aaron Powell But so what does this all mean for the patient?
- 7:06SPEAKER_00: I mean, are we just throwing out the biologics and steroids completely?
- 7:09SPEAKER_01: Oh, absolutely not.
- 7:10SPEAKER_01: No.
- 7:11SPEAKER_01: And the clinical guidelines from the sources are crystal clear on this.
- 7:14SPEAKER_01: Stem cell therapy is an adjunct.
- 7:17SPEAKER_00: Aaron Powell, an adjunct, meaning it's an extra option.
- 7:19SPEAKER_01: Aaron Powell Right.
- 7:20SPEAKER_01: It works alongside your current drugs, not as a replacement for them.
- 7:24SPEAKER_01: It specifically targets patients whose disease activity just persists even though they are on standard therapies.
- 7:30SPEAKER_00: Okay, so you keep the biologics running to prevent the broader fire, and you bring in the MSCs to do the targeted structural repair.
- 7:38SPEAKER_01: Exactly.
- 7:38SPEAKER_01: They are partners in the care plan.
- 7:40SPEAKER_00: That makes a lot of sense.
- 7:42SPEAKER_00: But now that we know what these cells do, we have to ask the most critical logistical questions.
- 7:46SPEAKER_00: Where do they actually come from?
- 7:48SPEAKER_01: Yeah, cell sourcing is a huge part of the conversation.
- 7:51SPEAKER_01: The clinical trials mainly point to two sources.
- 7:54SPEAKER_01: First, you have bone marrow stem cells.
- 7:57SPEAKER_00: Which usually come from the adult patient's own body, right?
- 8:00SPEAKER_01: Yes.
- 8:00SPEAKER_01: And they have been studied for a long time.
- 8:02SPEAKER_01: They're particularly good at helping with immune balance, but the field is really shifting its attention toward ethically sourced umbilical cord stem cells.
- 8:12SPEAKER_00: Oh, interesting.
- 8:13SPEAKER_00: So from healthy births?
- 8:14SPEAKER_01: Exactly.
- 8:15SPEAKER_01: They are derived from the umbilical cord, specifically a substance called Wharton's jelly, after a healthy turn delivery with full, strict donor consent.
- 8:23SPEAKER_00: Aaron Powell What is the advantage of using cord cells over your own bone marrow?
- 8:28SPEAKER_01: Well, fundamentally, they are just younger, much more robust cells.
- 8:33SPEAKER_01: They are incredibly rich in those specific healing signals and growth factors we just talked about.
- 8:38SPEAKER_00: Okay, the biological theory is beautiful, but I have to ask for the hard data here.
- 8:43SPEAKER_00: What is actually happening in the clinical trials with real living patients?
- 8:47SPEAKER_01: Right.
- 8:47SPEAKER_01: We have to look at the objective evidence.
- 8:48SPEAKER_01: The trials show that a portion of patients treated experience very real, documented improvements.
- 8:55SPEAKER_01: We are seeing lower inflammation markers in their blood work.
- 8:58SPEAKER_00: And what about the actual gut lining?
- 8:59SPEAKER_00: The burnt walls?
- 9:01SPEAKER_01: That's the best part.
- 9:02SPEAKER_01: When physicians perform endoscopies, they are seeing increased mucosal healing.
- 9:06SPEAKER_01: And on top of that, many patients just report improved daily gut symptoms.
- 9:11SPEAKER_00: Okay, but I have to play devil's advocate for a second.
- 9:13SPEAKER_00: What's the catch?
- 9:15SPEAKER_00: I mean, you are introducing a foreign biological agent into a hyperactive immune system.
- 9:20SPEAKER_00: What are the side effects?
- 9:22SPEAKER_01: That's a vital question.
- 9:23SPEAKER_01: We need a reality check here.
- 9:25SPEAKER_01: This is still considered an experimental adjunct, not a standard cure.
- 9:29SPEAKER_01: And the results vary from person to person.
- 9:31SPEAKER_00: So it's not a uniform response for everyone.
- 9:33SPEAKER_01: Not at all.
- 9:34SPEAKER_01: One person might see huge improvements, another might see very modest changes, but regarding safety in controlled settings, it is generally considered safe.
- 9:43SPEAKER_01: But mild side effects absolutely exist.
- 9:46SPEAKER_00: Like what?
- 9:47SPEAKER_00: What should a patient expect?
- 9:48SPEAKER_01: Because the cells are actively negotiating with the immune system, you might see a mild fever, general tiredness, or just some temporary discomfort right after the treatment.
- 9:58SPEAKER_01: Your body is working hard to process these new signals.
- 10:01SPEAKER_00: Which is exactly why the medical setting is so incredibly important.
- 10:04SPEAKER_00: You shouldn't just be doing this anywhere.
- 10:06SPEAKER_01: Exactly.
- 10:07SPEAKER_01: The clinic standards mean everything.
- 10:09SPEAKER_00: Which brings us to the real-world application.
- 10:12SPEAKER_00: Having established the experimental nature of this science, let's look at how Cyron is actually running their clinical model.
- 10:19SPEAKER_01: Yeah, they are a really fascinating example of how to do this right.
- 10:22SPEAKER_00: So they are a regenerative medicine center based in Kuala Lumpur, Malaysia.
- 10:28SPEAKER_00: And the sources point out they support a lot of local and international patients, particularly from Australia and the Middle East.
- 10:34SPEAKER_01: Right.
- 10:34SPEAKER_01: People are specifically traveling there for this structured approach.
- 10:38SPEAKER_00: And I found this fact really surprising.
- 10:40SPEAKER_00: Uh the name Sorona actually comes from a Celtic goddess of health and protection.
- 10:45SPEAKER_01: I love that detail.
- 10:46SPEAKER_01: It really reflects their whole ethos.
- 10:47SPEAKER_00: Yeah, it's all about safe, science-led care without all those exaggerated claims.
- 10:53SPEAKER_00: But how does that ethos translate to their lab standards?
- 10:56SPEAKER_01: They have incredibly stringent protocols.
- 10:58SPEAKER_01: For starters, they specifically use early passage WJMSCs.
- 11:02SPEAKER_00: Okay, wait.
- 11:03SPEAKER_00: Break that down for me.
- 11:04SPEAKER_00: WJMSCs is the Wharton's jelly from the umbilical cords, right?
- 11:08SPEAKER_00: But what does early passage mean?
- 11:10SPEAKER_01: Passage basically refers to how many times a cell has been forced to multiply in a lab.
- 11:15SPEAKER_01: Some places multiply them over and over to cut costs.
- 11:18SPEAKER_00: Oh, so they just stretch the supply as thin as possible.
- 11:21SPEAKER_01: Exactly.
- 11:22SPEAKER_01: But when you do that, the cell ages rapidly.
- 11:25SPEAKER_01: It loses its potency.
- 11:27SPEAKER_01: So by strictly using early passage cells, Saranocell ensures the cells are fresh, potent, and really capable of doing the biological work.
- 11:35SPEAKER_00: Wow, that's a huge distinction.
- 11:36SPEAKER_00: And they're producing everything under CGMP and ISO 9001 certified systems, right?
- 11:42SPEAKER_01: Yes, with BSL2 laboratory standards.
- 11:45SPEAKER_01: That basically guarantees sterility and viability.
- 11:48SPEAKER_01: Every batch is rigorously checked.
- 11:50SPEAKER_00: And the sources are also very explicit about what they do not do.
- 11:53SPEAKER_01: Right.
- 11:54SPEAKER_01: This is critical.
- 11:55SPEAKER_01: They do not use embryonic stem cells.
- 11:57SPEAKER_01: And they absolutely do not use experimental pluripotent stem cells.
- 12:00SPEAKER_00: Just strictly mature, ethically sourced MSCs.
- 12:03SPEAKER_00: And the delivery is minimally invasive, too, right?
- 12:05SPEAKER_01: Yeah, no open surgery at all for these IBD protocols.
- 12:08SPEAKER_01: It's usually just a standard IV infusion or in some musculoskeletal cases, targeted injections.
- 12:14SPEAKER_01: It's designed to minimize stress on the patient.
- 12:16SPEAKER_00: Okay, so let's talk about the actual patient experience there.
- 12:19SPEAKER_00: Because their medical team includes experts across internal medicine, neurology, rehabilitation.
- 12:25SPEAKER_00: And they operate on these three core commitments.
- 12:28SPEAKER_01: Right.
- 12:28SPEAKER_01: Clinical depth, compassionate care, and transparent advice.
- 12:32SPEAKER_00: I mean, clinical depth and compassionate care make sense, especially if you were traveling internationally.
- 12:37SPEAKER_00: But the transparent advice part really caught my eye.
- 12:40SPEAKER_01: It is arguably their most important commitment.
- 12:42SPEAKER_01: If a patient reaches out and their medical history shows they won't actually benefit from the therapy, Cyren SL will honestly just tell them no.
- 12:50SPEAKER_00: Wait, really?
- 12:51SPEAKER_00: They just turn the business away.
- 12:52SPEAKER_01: Yes.
- 12:53SPEAKER_01: They refuse to perform the treatment if the science doesn't support it for that specific patient.
- 12:58SPEAKER_01: It is about building long-term trust, not just selling a procedure.
- 13:02SPEAKER_00: Aaron Powell, which is so refreshing in a space that can be, well, a little chaotic.
- 13:06SPEAKER_01: It really is.
- 13:07SPEAKER_01: It shifts the dynamic back to ethical, realistic care.
- 13:10SPEAKER_00: So synthesizing all of this for you listening at home, we have covered a lot of ground today.
- 13:16SPEAKER_00: We looked at the chronic battleground of IBD and just how limiting current drugs can be when it comes to actual tissue repair.
- 13:23SPEAKER_01: Right, the fire extinguisher versus the burnt house.
- 13:26SPEAKER_00: Exactly.
- 13:26SPEAKER_00: And we've seen how MSC therapy, when it's practiced responsibly by clinics like SIRA and SL, offers a really promising, though still evolving, adjunct to help repair the gut.
- 13:38SPEAKER_01: And if you are navigating a complex chronic condition, I mean it can be incredibly overwhelming.
- 13:43SPEAKER_01: But understanding the why behind these treatments is just crucial.
- 13:47SPEAKER_00: Yeah, knowing that regenerative medicine is a partner to traditional care, not a magic eraser.
- 13:51SPEAKER_01: Exactly.
- 13:52SPEAKER_01: It empowers you to make informed decisions without falling victim to false hope.
- 13:56SPEAKER_00: Well said.
- 13:56SPEAKER_00: And I want to leave you with a final thought to ponder today.
- 13:59SPEAKER_00: We have just talked about how mesenchymal stem cells can be directed to essentially act as diplomats, right?
- 14:05SPEAKER_00: Negotiating this truce with a misfiring immune system in the gut while simultaneously rebuilding tissue.
- 14:11SPEAKER_01: Right, calming the alarms and repairing the damage.
- 14:14SPEAKER_00: Exactly.
- 14:15SPEAKER_00: So if we can harness that, what other incurable inflammatory fires in the human body might this exact same cellular diplomacy eventually extinguish?
- 14:26SPEAKER_01: Oh, that is the exact question driving the future of this entire field.
- 14:30SPEAKER_01: It is a very exciting thought.
- 14:31SPEAKER_00: It really is.
- 14:32SPEAKER_00: Well, thank you for joining us today on this deep dive into the evolving world regenerative medicine.
- 14:36SPEAKER_00: We'll catch you next time.